Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, March 11, 2015, 115 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $183.00 to $317,250,000.00.

Highlighted Stocks Traded by Insiders:

Physicians Realty (DOC) - FREE Research Report

Black Albert Jr, who is Director at Physicians Realty, bought 3,160 shares at $16.06 on March 11, 2015. Following this transaction, the Director owned 25,005 shares meaning that the stake was boosted by 14.47% with the 3,160-share transaction.

The shares most recently traded at $16.34, up $0.28, or 1.71% since the insider transaction.

The average volume for Physicians Realty has been 766,400 shares per day over the past 30 days. Physicians Realty has a market cap of $763.8 million and is part of the financial sector and real estate industry. Shares are down 3.07% year-to-date as of the close of trading on Wednesday.

Physicians Realty Trust, a self-managed healthcare real estate company, focuses on the acquisition, development, ownership, and management of healthcare properties that are leased to physicians, hospitals, and healthcare delivery systems. The stock currently has a dividend yield of 5.58%. Currently, there are 7 analysts who rate Physicians Realty a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on DOC - FREE

TheStreet Quant Ratings

rates Physicians Realty as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full

Physicians Realty Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Synacor (SYNC) - FREE Research Report

Ginsberg Gary L, who is Director at Synacor, bought 20,000 shares at $2.34 on March 11, 2015. Following this transaction, the Director owned 20,000 shares meaning that the stake was boosted by 100% with the 20,000-share transaction.

The shares most recently traded at $2.34, up $0.00, or 0.12% since the insider transaction. Historical insider transactions for Synacor go as follows:

  • 4-Week # shares bought: 51,000
  • 4-Week # shares sold: 11,500
  • 12-Week # shares bought: 51,000
  • 12-Week # shares sold: 11,500
  • 24-Week # shares bought: 51,000
  • 24-Week # shares sold: 11,500

The average volume for Synacor has been 164,800 shares per day over the past 30 days. Synacor has a market cap of $64.6 million and is part of the technology sector and internet industry. Shares are up 15% year-to-date as of the close of trading on Wednesday.

Synacor, Inc. provides startpages and homescreens, TV Everywhere solutions, Identity Management services, and various cloud-based services across a range of devices for cable, satellite, telecom, and consumer electronics companies in the United States, and the United Kingdom. Currently, there are no analysts who rate Synacor a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SYNC - FREE

TheStreet Quant Ratings

rates Synacor as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full

Synacor Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

NxStage Medical (NXTM) - FREE Research Report

Turk Joseph E Jr, who is President at NxStage Medical, sold 1,500 shares at $16.44 on March 11, 2015. Following this transaction, the President owned 126,663 shares meaning that the stake was reduced by 1.17% with the 1,500-share transaction.

The shares most recently traded at $17.25, up $0.81, or 4.7% since the insider transaction. Historical insider transactions for NxStage Medical go as follows:

  • 4-Week # shares bought: 10,150
  • 4-Week # shares sold: 1,500
  • 12-Week # shares bought: 10,150
  • 12-Week # shares sold: 7,500
  • 24-Week # shares bought: 10,150
  • 24-Week # shares sold: 38,816

The average volume for NxStage Medical has been 379,500 shares per day over the past 30 days. NxStage Medical has a market cap of $1.0 billion and is part of the health care sector and health services industry. Shares are down 5.02% year-to-date as of the close of trading on Wednesday.

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Currently, there are 4 analysts who rate NxStage Medical a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NXTM - FREE

TheStreet Quant Ratings

rates NxStage Medical as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow. Get the full

NxStage Medical Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null